Stay up-to-date.
Media

Press Releases

Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics 150 150 Myonexus Therapeutics

Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics

Companies to Exercise Purchase Option Agreement Following Positive, Preliminary Data in Limb-Girdle Muscular Dystrophy Type 2E Program NEW ALBANY, Ohio, February 27, 2019 — Myonexus Therapeutics, a clinical-stage gene therapy company developing first-ever corrective gene therapies for Limb-girdle muscular dystrophies (LGMD), announced today Sarepta will exercise its option to purchase Myonexus for $165 million. The…

read more
Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D) 150 150 Myonexus Therapeutics

Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D)

NEW ALBANY, Ohio, January 2, 2019 — Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for MYO-102, a novel gene therapy candidate for alpha-sarcoglycanopathy, also known as Limb Girdle Muscular Dystrophy Type 2D (LGMD2D). Myonexus Therapeutics is a clinical-stage gene therapy company developing first-ever corrective…

read more
Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Betasarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E 150 150 Myonexus Therapeutics

Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Betasarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E

First-in-human trial of MYO-101 based on promising pre-clinical results offering the first corrective approach for LGMD2E NEW ALBANY, Ohio, November 8, 2018 — Myonexus Therapeutics, a clinical-stage gene therapy company developing first-ever corrective gene therapies for limb girdle muscular dystrophies (LGMD), in collaboration with Nationwide Children’s Hospital’s Center for Gene Therapy and Sarepta Therapeutics, announced…

read more

In the News

Sign-up to get updates from Myonexus Therapeutics!